Effect of the A118G polymorphism on binding affinity, potency and agonist-mediated endocytosis, desensitization, and resensitization of the human mu-opioid receptor.
paper
Cited
Public
Unavailable
- Authors
- Beyer, Andrea; Koch, Thomas; SchrΓΆder, Helmut; Schulz, Stefan; HΓΆllt, Volker
- Year
- 2004
- Journal
- Journal of neurochemistry
- PMID
- 15086512
- DOI
- 10.1111/j.1471-4159.2004.02340.x
The most prevalent single-nucleotide polymorphism (SNP) A118G in the human mu-opioid receptor gene predicts an amino acid change from an asparagine residue to an aspartatic residue in amino acid position 40. This N40D mutation, which has been implicated in the development of opioid addiction, was previously reported to result in an increased beta-endorphin binding affinity and a decreased potency of morphine-6-glucuronide. Therefore, in the present study we have investigated whether this mutation might affect the binding affinity, potency, and/or the agonist-induced desensitization, internalization and resensitization of the human mu-opioid receptor stably expressed in human embryonic kidney 293 cells. With the exception of a reduced expression level of N40D compared to human mu-opioid receptor (hMOR) in HEK293 cells, our analyses revealed no marked functional differences between N40D and wild-type receptor. Morphine, morphine-6-glucuronide and beta-endorphin revealed similar binding affinities and potencies for both receptors. Both the N40D-variant receptor and hMOR exhibited robust receptor internalization in the presence of the opioid peptide [d-Ala(2),N-MePhe(4),Glyol(5)]enkephalin (DAMGO) and beta-endorphin but not in response to morphine or morphine-6-glucuronide. After prolonged treatment with morphine, morphine-6-glucuronide or beta-endorphin both receptors showed similiar desensitization time courses. In addition, the receptor resensitization rates were nearly identical for both receptor types.
No figures extracted from this document.
No chunks β full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
No citations found.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| <i>Kappa</i>-opioid receptor gene (<i>OPRK1</i>) variations associated with opioid abstinence behaviors among chronic heroin users. | Greenwald MK et al. | β | 2025 | β |
| The Possible Mechanistic Basis of Individual Susceptibility to Spike Protein Injury. | Halma M et al. | β | 2025 | β |
| Functional differences in the mu opioid receptor SNP 118A>G are dependent on receptor splice-variant andΒ agonist-specific recruitment of Ξ²-arrestin. | Patrick C et al. | β | 2024 | β |
| G protein-coupled receptor (GPCR) pharmacogenomics. | Thompson MD et al. | β | 2024 | β |
| Introduction: Approved treatments for alcohol use disorder by regulatory agencies. | Camarini R et al. | β | 2024 | β |
| Allele frequency and genotype distribution of the opioid receptor ΞΌ-1 (OPRM1) A118G polymorphism in the Western Saudi population. | Bagher AM et al. | β | 2023 | β |
| Genetic Factors Associated with Morphine Consumption in Women Undergoing Laparoscopic Cholecystectomy: A Prospective Cohort Study. | Elgendy HM et al. | β | 2023 | β |
| Dexamethasone Does not Compensate for Local Anesthetic Cytotoxic Effects on Tenocytes: Morphine or Morphine Plus Dexamethasone May Be a SafeΒ Alternative. | Oeyen AL et al. | β | 2022 | β |
| Sublingual buprenorphine/naloxone treatment is not affected by OPRM1 A118G and BDNF Va66Met polymorphisms, but alters the plasma beta-endorphin and BDNF levels in individuals with opioid use disorder. | Kaya-AkyΓΌzlΓΌ D et al. | β | 2022 | β |
| Variation in the Mu-Opioid Receptor (OPRM1) and Offspring Sex Are Associated With Maternal Behavior in Rhesus Macaques (<i>Macaca mulatta</i>). | Wood EK et al. | β | 2022 | β |
| Association of Dopamine Transporter Gene with Heroin Dependence in an Indian Subpopulation from Manipur. | Koijam AS et al. | β | 2021 | β |
| Epigenetic and Genetic Factors Associated With Opioid Use Disorder: Are These Relevant to African American Populations. | Blackwood CA et al. | β | 2021 | β |
| Genetic Vulnerability to Opioid Addiction. | Reed B et al. | β | 2021 | β |
| Translational Research in Nicotine Addiction. | Fisher ML et al. | β | 2021 | β |
| Addiction associated N40D mu-opioid receptor variant modulates synaptic function in human neurons. | Halikere A et al. | β | 2020 | β |
| Differential sensitivity of human neurons carrying ΞΌ opioid receptor (MOR) N40D variants in response to ethanol. | Scarnati MS et al. | β | 2020 | β |
| Molecular Basis of Opioid Action: From Structures to New Leads. | Manglik A | β | 2020 | β |
| Relapse-like behavior in a mouse model of the OPRM1 (mu-opioid receptor) A118G polymorphism: Examination with intravenous oxycodone self-administration. | Zhang Y et al. | β | 2020 | β |
| Systematic Review and Meta-Analysis of Genetic Risk of Developing Chronic Postsurgical Pain. | Chidambaran V et al. | β | 2020 | β |
| An update on the safety of prescribing opioids in pediatrics. | Parikh JM et al. | β | 2019 | β |
| Dopamine and opioid systems adaptation in alcoholism revisited: Convergent evidence from positron emission tomography and postmortem studies. | Hansson AC et al. | β | 2019 | β |
| Molecular Imaging of Opioid and Dopamine Systems: Insights Into the Pharmacogenetics of Opioid Use Disorders. | Burns JA et al. | β | 2019 | β |
| Stabilization of ΞΌ-opioid receptor facilitates its cellular translocation and signaling. | Zhu C et al. | β | 2019 | β |
| The association between the OPRM1 A118G polymorphism and addiction in a Turkish population. | TΓΌrkan H et al. | β | 2019 | β |
| Addiction associated N40D mu-opioid receptor variant modulates synaptic function in human neurons | Halikere A et al. | β | 2018 | β |
| Dynamic lateral organization of opioid receptors (kappa, mu<sub>wt</sub> and mu<sub>N40D</sub> ) in the plasma membrane at the nanoscale level. | Rogacki MK et al. | β | 2018 | β |
| Implication of OPRM1 A118G Polymorphism in Opioids Addicts in Pakistan: In vitro and In silico Analysis. | Ahmed M et al. | β | 2018 | β |
| The Cholinergic System as a Treatment Target for Opioid Use Disorder. | Jensen KP et al. | β | 2018 | β |
| Convergent Balancing Selection on the Mu-Opioid Receptor in Primates. | Sweeney CG et al. | β | 2017 | β |
| DNA methylation at the mu-1 opioid receptor gene (<i>OPRM1</i>) promoter predicts preoperative, acute, and chronic postsurgical pain after spine fusion. | Chidambaran V et al. | β | 2017 | β |
| Similarities and Differences in Genetics. | Zhang Y et al. | β | 2017 | β |
| A gene-by-sex interaction for nicotine reward: evidence from humanized mice and epidemiology. | Bernardi RE et al. | β | 2016 | β |
| Alcohol addiction and the mu-opioid receptor. | Berrettini W | β | 2016 | β |
| An Expert Review of Pharmacogenomics of Sickle Cell Disease Therapeutics: Not Yet Ready for Global Precision Medicine. | Mnika K et al. | β | 2016 | β |
| Association of the OPRM1 Variant rs1799971 (A118G) with Non-Specific Liability to Substance Dependence in a Collaborative de novo Meta-Analysis of European-Ancestry Cohorts. | Schwantes-An TH et al. | β | 2016 | β |
| Effects of fentanyl administration on locomotor response in horses with the G57C ΞΌ-opioid receptor polymorphism. | Wetmore LA et al. | β | 2016 | β |
| Genetic variants associated with thermal pain sensitivity in a paediatric population. | Matic M et al. | β | 2016 | β |
| Morphine-induced antinociception and reward in "humanized" mice expressing the mu opioid receptor A118G polymorphism. | Henderson-Redmond AN et al. | β | 2016 | β |
| Opioid Antagonists and the A118G Polymorphism in the ΞΌ-Opioid Receptor Gene: Effects of GSK1521498 and Naltrexone in Healthy Drinkers Stratified by OPRM1 Genotype. | Ziauddeen H et al. | β | 2016 | β |
| Opioid neuroscience for addiction medicine: From animal models to FDA approval for alcohol addiction. | Berrettini W | β | 2016 | β |
| Association between Opioid Receptor mu 1 (OPRM1) Gene Polymorphisms and Tobacco and Alcohol Consumption in a Spanish Population. | FrancΓ¨s F et al. | β | 2015 | β |
| Association of OPRM1 A118G variant with risk of morphine-induced respiratory depression following spine fusion in adolescents. | Chidambaran V et al. | β | 2015 | β |
| Cellular signalling of non-synonymous single-nucleotide polymorphisms of the human ΞΌ-opioid receptor (OPRM1). | Knapman A et al. | β | 2015 | β |
| Cis-Expression Quantitative Trait Loci Mapping Reveals Replicable Associations with Heroin Addiction in OPRM1. | Hancock DB et al. | β | 2015 | β |
| Cocaine-induced suppression of saccharin intake and morphine modulation of CaΒ²βΊ channel currents in sensory neurons of OPRM1 A118G mice. | Freet CS et al. | β | 2015 | β |
| Cortisol Stress Response in Men and Women Modulated Differentially by the Mu-Opioid Receptor Gene Polymorphism OPRM1 A118G. | Lovallo WR et al. | β | 2015 | β |
| Functional mu opioid receptor polymorphism (OPRM1 A(118) G) associated with heroin use outcomes in Caucasian males: A pilot study. | Woodcock EA et al. | β | 2015 | β |
| Receptor Reserve Moderates Mesolimbic Responses to Opioids in a Humanized Mouse Model of the OPRM1 A118G Polymorphism. | Robinson JE et al. | β | 2015 | β |
| Regional brain [(11)C]carfentanil binding following tobacco smoking. | Domino EF et al. | β | 2015 | β |
| ΞΌ-Opioid Receptor Gene A118Β G Variants and Persistent Pain Symptoms Among Men and Women Experiencing Motor VehicleΒ Collision. | Linnstaedt SD et al. | β | 2015 | β |
| A118G polymorphism in the ΞΌ-opioid receptor gene and levels of Ξ²-endorphin are associated with provoked vestibulodynia and pressure pain sensitivity. | Heddini U et al. | β | 2014 | β |
| Assessment of opioid receptor ΞΌ1 gene A118G polymorphism and its association with pain intensity in patients with fibromyalgia. | Solak Γ et al. | β | 2014 | β |
| Association between common genetic variants in the opioid pathway and smoking behaviors in Chinese men. | Fang J et al. | β | 2014 | β |
| Buprenorphine signalling is compromised at the N40D polymorphism of the human ΞΌ opioid receptor in vitro. | Knapman A et al. | β | 2014 | β |
| Initial responses to the first dose of nicotine in novel smokers: the role of exposure to environmental smoking and genetic predisposition. | Schuck K et al. | β | 2014 | β |
| Letting the gene out of the bottle: OPRM1 interactions. | Belfer I et al. | β | 2014 | β |
| OPRM1 A118G gene variant and postoperative opioid requirement: a systematic review and meta-analysis. | Hwang IC et al. | β | 2014 | β |
| Pharmacogenetics of the G protein-coupled receptors. | Thompson MD et al. | β | 2014 | β |
| A machine-learned knowledge discovery method for associating complex phenotypes with complex genotypes. Application to pain. | LΓΆtsch J et al. | β | 2013 | β |
| Analgesia and central side-effects: two separate dimensions of morphine response. | Droney JM et al. | β | 2013 | β |
| Combined analysis of circulating Ξ²-endorphin with gene polymorphisms in OPRM1, CACNAD2 and ABCB1 reveals correlation with pain, opioid sensitivity and opioid-related side effects. | Rhodin A et al. | β | 2013 | β |
| Consequences of the 118A>G polymorphism in the OPRM1 gene: translation from bench to bedside? | Mura E et al. | β | 2013 | β |
| Dual growth of adolescent smoking and drinking: evidence for an interaction between the mu-opioid receptor (OPRM1) A118G polymorphism and sex. | Kleinjan M et al. | β | 2013 | β |
| Epigenetics: a promising paradigm for better understanding and managing pain. | Seo S et al. | β | 2013 | β |
| Functional characteristics of the naked mole rat ΞΌ-opioid receptor. | Busch-Dienstfertig M et al. | β | 2013 | β |
| Gene polymorphisms of OPRM1 A118G and ABCB1 C3435T may influence opioid requirements in Chinese patients with cancer pain. | Gong XD et al. | β | 2013 | β |
| Genetic variability at COMT but not at OPRM1 and UGT2B7 loci modulates morphine analgesic response in acute postoperative pain. | De Gregori M et al. | β | 2013 | β |
| Lack of association of OPRM1 genotype and smoking cessation. | MunafΓ² MR et al. | β | 2013 | β |
| Opioid pharmacogenetics of alcohol addiction. | Berrettini W | β | 2013 | β |
| Opioid receptor polymorphism A118G associated with clinical severity in a drug overdose population. | Manini AF et al. | β | 2013 | β |
| Prevention of chronic postoperative pain: cellular, molecular, and clinical insights for mechanism-based treatment approaches. | Deumens R et al. | β | 2013 | β |
| Regulation of ΞΌ-opioid receptors: desensitization, phosphorylation, internalization, and tolerance. | Williams JT et al. | β | 2013 | β |
| The comorbidity of insomnia, chronic pain, and depression: dopamine as a putative mechanism. | Finan PH et al. | β | 2013 | β |
| The correlation between post-operative fentanyl requirements and <i>ΞΌ</i>-opioid receptor gene A118G polymorphism in patients undergoing radical gastrectomy. | Zhang F et al. | β | 2013 | β |
| The ΞΌ-opioid receptor and treatment response to naltrexone. | Thorsell A | β | 2013 | β |
| ΞΌ-Opioid receptor gene (OPRM1) polymorphism A118G: lack of association in Finnish populations with alcohol dependence or alcohol consumption. | Rouvinen-LagerstrΓΆm N et al. | β | 2013 | β |
| Β΅-opioid receptor gene variant OPRM1 118 A>G: a summary of its molecular and clinical consequences for pain. | Walter C et al. | β | 2013 | β |
| A common single nucleotide polymorphism A118G of theΒ ΞΌ opioid receptor alters its N-glycosylation and protein stability. | Huang P et al. | β | 2012 | β |
| A systematic review of the A118G (Asn40Asp) variant of OPRM1 in relation to smoking initiation, nicotine dependence and smoking cessation. | Verhagen M et al. | β | 2012 | β |
| Delta and kappa opioid receptor polymorphisms influence the effects of naltrexone on subjective responses to alcohol. | Ashenhurst JR et al. | β | 2012 | β |
| Ethnic-specific meta-analyses of association between the OPRM1 A118G polymorphism and alcohol dependence among Asians and Caucasians. | Chen D et al. | β | 2012 | β |
| Influence of the OPRM1 A118G polymorphism on alcohol-induced euphoria, risk for alcoholism and the clinical efficacy of naltrexone. | Setiawan E et al. | β | 2012 | β |
| Influence of the OPRM1 gene polymorphism upon children's degree of withdrawal and brain activation in response to facial expressions. | Bertoletti E et al. | β | 2012 | β |
| Mu opioid receptor (OPRM1) as a predictor of treatment outcome in opiate-dependent individuals of Arab descent. | Al-Eitan LN et al. | β | 2012 | β |
| Opiate addiction and cocaine addiction: underlying molecular neurobiology and genetics. | Kreek MJ et al. | β | 2012 | β |
| Pharmacogenomic considerations in opioid analgesia. | Vuilleumier PH et al. | β | 2012 | β |
| Testing multiple levels of influence in the intergenerational transmission of alcohol disorders from a developmental perspective: the example of alcohol use promoting peers and ΞΌ-opioid receptor M1 variation. | Chassin L et al. | β | 2012 | β |
| The A118G single-nucleotide polymorphism of human ΞΌ-opioid receptor gene and use of labor analgesia. | Pettersson FD et al. | β | 2012 | β |
| The genetics of the opioid system and specific drug addictions. | Levran O et al. | β | 2012 | β |
| The promise of pharmacogenetics in labor analgesiaβ¦tantalizing, but not there yet. | Wong CA | β | 2012 | β |
| The role of the Asn40Asp polymorphism of the mu opioid receptor gene (OPRM1) on alcoholism etiology and treatment: a critical review. | Ray LA et al. | β | 2012 | β |
| Translational genetic approaches to substance use disorders: bridging the gap between mice and humans. | Palmer AA et al. | β | 2012 | β |
| Child ΞΌ-opioid receptor gene variant influences parent-child relations. | Copeland WE et al. | β | 2011 | β |
| Chronic neuropathic pain in mice reduces ΞΌ-opioid receptor-mediated G-protein activity in the thalamus. | Hoot MR et al. | β | 2011 | β |
| Combined catechol-O-methyltransferase and mu-opioid receptor gene polymorphisms affect morphine postoperative analgesia and central side effects. | Kolesnikov Y et al. | β | 2011 | β |
| Elucidation of mu-Opioid Gene Structure: How Genetics Can Help Predict Responses to Opioids. | Diatchenko L et al. | β | 2011 | β |
| Evolving knowledge of opioid genetics in cancer pain. | Droney J et al. | β | 2011 | β |
| Functional polymorphism of the mu-opioid receptor gene (OPRM1) influences reinforcement learning in humans. | Lee MR et al. | β | 2011 | β |
| Human Mu Opioid Receptor (OPRM1 A118G) polymorphism is associated with brain mu-opioid receptor binding potential in smokers. | Ray R et al. | β | 2011 | β |
| Micro opioid receptor A118G polymorphism and post-operative pain: opioids' effects on heterozygous patients. | De Capraris A et al. | β | 2011 | β |
| No evidence of association between 118A>G OPRM1 polymorphism and heroin dependence in a large Bulgarian case-control sample. | Nikolov MA et al. | β | 2011 | β |
| OPRM1 gene variation influences hypothalamic-pituitary-adrenal axis function in response to a variety of stressors in rhesus macaques. | Schwandt ML et al. | β | 2011 | β |
| Pharmacogenetics of alcohol, nicotine and drug addiction treatments. | Sturgess JE et al. | β | 2011 | β |
| Pharmacogenomics of the human Β΅-opioid receptor. | Kasai S et al. | β | 2011 | β |
| Pharmacological consequence of the A118G ΞΌ opioid receptor polymorphism on morphine- and fentanyl-mediated modulation of CaΒ²βΊ channels in humanized mouse sensory neurons. | Mahmoud S et al. | β | 2011 | β |
| Social hedonic capacity is associated with the A118G polymorphism of the mu-opioid receptor gene (OPRM1) in adult healthy volunteers and psychiatric patients. | Troisi A et al. | β | 2011 | β |
| Association of human micro-opioid receptor gene polymorphism A118G with fentanyl analgesia consumption in Chinese gynaecological patients. | Zhang W et al. | β | 2010 | β |
| Genetic influences on the dynamics of pain and affect in fibromyalgia. | Finan PH et al. | β | 2010 | β |
| Initial evidence of an association between OPRM1 and adolescent alcohol misuse. | Miranda R et al. | β | 2010 | β |
| Ligand-directed c-Jun N-terminal kinase activation disrupts opioid receptor signaling. | Melief EJ et al. | β | 2010 | β |
| Observational study of the effect of mu-opioid receptor genetic polymorphism on intrathecal opioid labor analgesia and post-cesarean delivery analgesia. | Wong CA et al. | β | 2010 | β |
| OPRM1 SNP (A118G): involvement in disease development, treatment response, and animal models. | Mague SD et al. | β | 2010 | β |
| Pharmacogenetics: a tool for identifying genetic factors in drug dependence and response to treatment. | Mroziewicz M et al. | β | 2010 | β |
| Single-nucleotide polymorphism (A118G) in exon 1 of OPRM1 gene causes alteration in downstream signaling by mu-opioid receptor and may contribute to the genetic risk for addiction. | Deb I et al. | β | 2010 | β |
| Tolerance and withdrawal from prolonged opioid use in critically ill children. | Anand KJ et al. | β | 2010 | β |
| Trial Protocol: Using genotype to tailor prescribing of nicotine replacement therapy: a randomised controlled trial assessing impact of communication upon adherence. | Marteau TM et al. | β | 2010 | β |
| A common human micro-opioid receptor genetic variant diminishes the receptor signaling efficacy in brain regions processing the sensory information of pain. | Oertel BG et al. | β | 2009 | β |
| Association between OPRM1 gene polymorphisms and fentanyl sensitivity in patients undergoing painful cosmetic surgery. | Fukuda K et al. | β | 2009 | β |
| Bidirectional translational research: Progress in understanding addictive diseases. | Kreek MJ et al. | β | 2009 | β |
| Current evidence for a modulation of low back pain by human genetic variants. | Tegeder I et al. | β | 2009 | β |
| Ethnicity and OPRM variant independently predict pain perception and patient-controlled analgesia usage for post-operative pain. | Tan EC et al. | β | 2009 | β |
| Expansion of the human mu-opioid receptor gene architecture: novel functional variants. | Shabalina SA et al. | β | 2009 | β |
| Functional characterization of human variants of the mu-opioid receptor gene. | Ravindranathan A et al. | β | 2009 | β |
| Individualized pain medicine. | Kim H et al. | β | 2009 | β |
| Meta-analysis of the relevance of the OPRM1 118A>G genetic variant for pain treatment. | Walter C et al. | β | 2009 | β |
| Mouse model of OPRM1 (A118G) polymorphism has sex-specific effects on drug-mediated behavior. | Mague SD et al. | β | 2009 | β |
| Nicotine withdrawal sensitivity, linkage to chr6q26, and association of OPRM1 SNPs in the SMOking in FAMilies (SMOFAM) sample. | Hardin J et al. | β | 2009 | β |
| OPRM1 Asn40Asp predicts response to naltrexone treatment: a haplotype-based approach. | Oroszi G et al. | β | 2009 | β |
| Stress, alcohol and drug interaction: an update of human research. | Uhart M et al. | β | 2009 | β |
| The potential of pharmacogenomics to treat drug addiction. | Haile CN et al. | β | 2009 | β |
| Variation in the mu-opioid receptor gene (OPRM1) is associated with dispositional and neural sensitivity to social rejection. | Way BM et al. | β | 2009 | β |
| A functional polymorphism of the micro-opioid receptor gene is associated with completed suicides. | Hishimoto A et al. | β | 2008 | β |
| Analgesic requirements after major abdominal surgery are associated with OPRM1 gene polymorphism genotype and haplotype. | Hayashida M et al. | β | 2008 | β |
| An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. | Anton RF et al. | β | 2008 | β |
| Association of dopamine and opioid receptor genetic polymorphisms with response to methadone maintenance treatment. | Crettol S et al. | β | 2008 | β |
| Candidate gene polymorphisms predicting individual sensitivity to opioids. | Kasai S et al. | β | 2008 | β |
| Differential opioid action on sensory and affective cerebral pain processing. | Oertel BG et al. | β | 2008 | β |
| Effects of opioid receptor gene variation on targeted nalmefene treatment in heavy drinkers. | Arias AJ et al. | β | 2008 | β |
| Genetic basis for predicting response to naltrexone in the treatment of alcohol dependence. | Anton RF | β | 2008 | β |
| Genetic contributions to pain: a review of findings in humans. | Fillingim RB et al. | β | 2008 | β |
| [Genetic polymorphisms and opioid therapies]. | Landau R | β | 2008 | β |
| Genetic variability of the mu-opioid receptor influences intrathecal fentanyl analgesia requirements in laboring women. | Landau R et al. | β | 2008 | β |
| G protein-coupled receptor pharmacogenetics. | Thompson MD et al. | β | 2008 | β |
| Human expression variation in the mu-opioid receptor is paralleled in rhesus macaque. | Vallender EJ et al. | β | 2008 | β |
| Interindividual variability of methadone response: impact of genetic polymorphism. | Li Y et al. | β | 2008 | β |
| Limited effects of beta-endorphin compared to loperamide or fentanyl in a neuroendocrine biomarker assay in non-human primates. | Butelman ER et al. | β | 2008 | β |
| Naltrexone alone and with sertraline for the treatment of alcohol dependence in Alaska natives and non-natives residing in rural settings: a randomized controlled trial. | O'Malley SS et al. | β | 2008 | β |
| Opioid tolerance development: a pharmacokinetic/pharmacodynamic perspective. | Dumas EO et al. | β | 2008 | β |
| Pharmacogenetic insights into codeine analgesia: implications to pediatric codeine use. | Madadi P et al. | β | 2008 | β |
| Pharmacogenetic treatments for drug addiction: alcohol and opiates. | Haile CN et al. | β | 2008 | β |
| Role of pharmacogenetics in variable response to drugs: focus on opioids. | Kadiev E et al. | β | 2008 | β |
| The genetics of alcohol and other drug dependence. | Dick DM et al. | β | 2008 | β |
| The value of CYP2D6 and OPRM1 pharmacogenetic testing for opioid therapy. | Reynolds KK et al. | β | 2008 | β |
| Tobacco addiction. | Hatsukami DK et al. | β | 2008 | β |
| Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings. | Johnson BA | β | 2008 | β |
| Variation at the mu-opioid receptor gene (OPRM1) influences attachment behavior in infant primates. | Barr CS et al. | β | 2008 | β |
| Association of the mu-opioid receptor gene with smoking cessation. | MunafΓ² MR et al. | β | 2007 | β |
| Current evidence for a modulation of nociception by human genetic polymorphisms. | LΓΆtsch J et al. | β | 2007 | β |
| Effect of mu-opioid receptor gene polymorphisms on heroin-induced subjective responses in a Chinese population. | Zhang D et al. | β | 2007 | β |
| micro-Opioid receptor activation prevents acute hepatic inflammation and cell death. | Chakass D et al. | β | 2007 | β |
| Modulation of Ca2+ channels by heterologously expressed wild-type and mutant human micro-opioid receptors (hMORs) containing the A118G single-nucleotide polymorphism. | Margas W et al. | β | 2007 | β |
| Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study. | Gelernter J et al. | β | 2007 | β |
| Pharmacogenetics of opioids. | Somogyi AA et al. | β | 2007 | β |
| Polymorphisms in the mu-opioid receptor gene (OPRM1) and the implications for alcohol dependence in humans. | van der Zwaluw CS et al. | β | 2007 | β |
| Population-specific effects of the Asn40Asp polymorphism at the mu-opioid receptor gene (OPRM1) on HPA-axis activation. | Hernandez-Avila CA et al. | β | 2007 | β |
| The Asp40 mu-opioid receptor allele does not predict naltrexone treatment efficacy in heavy drinkers. | Mitchell JM et al. | β | 2007 | β |
| The opioid system in alcohol and drug dependence: family-based association study. | Xuei X et al. | β | 2007 | β |
| The single nucleotide polymorphism A118G alters functional properties of the human mu opioid receptor. | Kroslak T et al. | β | 2007 | β |
| A genetic association study of the functional A118G polymorphism of the human mu-opioid receptor gene in patients with acute and chronic pain. | Janicki PK et al. | β | 2006 | β |
| Altered levels of basal cortisol in healthy subjects with a 118G allele in exon 1 of the Mu opioid receptor gene. | Bart G et al. | β | 2006 | β |
| Association between two mu-opioid receptor gene (OPRM1) haplotype blocks and drug or alcohol dependence. | Zhang H et al. | β | 2006 | β |
| Association of an Asn40Asp (A118G) polymorphism in the mu-opioid receptor gene with substance dependence: a meta-analysis. | Arias A et al. | β | 2006 | β |
| Association of mu-opioid receptor gene polymorphism (A118G) with variations in morphine consumption for analgesia after total knee arthroplasty. | Chou WY et al. | β | 2006 | β |
| Current evidence for a genetic modulation of the response to analgesics. | LΓΆtsch J et al. | β | 2006 | β |
| Drugs and genotypes: how pharmacogenetic information could improve smoking cessation treatment. | Lee AM et al. | β | 2006 | β |
| Genetic moderators of naltrexone's effects on alcohol cue reactivity. | McGeary JE et al. | β | 2006 | β |
| Genotype and smoking history affect risk of levodopa-induced dyskinesias in Parkinson's disease. | Strong JA et al. | β | 2006 | β |
| Morphine-6-glucuronide: morphine's successor for postoperative pain relief? | van Dorp EL et al. | β | 2006 | β |
| Mu opioid receptor A118G polymorphism in association with striatal opioid neuropeptide gene expression in heroin abusers. | Drakenberg K et al. | β | 2006 | β |
| Pharmacogenetics of opioid receptors and addiction. | Mayer P et al. | β | 2006 | β |
| Relevance of frequent mu-opioid receptor polymorphisms for opioid activity in healthy volunteers. | LΓΆtsch J et al. | β | 2006 | β |
| Searching for polymorphisms that affect gene expression and mRNA processing: example ABCB1 (MDR1). | Wang D et al. | β | 2006 | β |
| Symbiotic relationship of pharmacogenetics and drugs of abuse. | Rutter JL | β | 2006 | β |
| Targeting treatments for alcohol dependence: the pharmacogenetics of naltrexone. | Oslin DW et al. | β | 2006 | β |
| The mu-opioid receptor gene polymorphism 118A>G depletes alfentanil-induced analgesia and protects against respiratory depression in homozygous carriers. | Oertel BG et al. | β | 2006 | β |
| The mu-opioid receptor polymorphism A118G predicts cortisol responses to naloxone and stress. | Chong RY et al. | β | 2006 | β |
| Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G. | Zhang Y et al. | β | 2005 | β |
| Are mu-opioid receptor polymorphisms important for clinical opioid therapy? | LΓΆtsch J et al. | β | 2005 | β |
| [Are polymorphisms in the mu-opioid receptor important for opioid therapy?]. | LΓΆtsch J et al. | β | 2005 | β |
| Detection of beta-endorphin in the cerebrospinal fluid after intrastriatal microinjection into the rat brain. | HΓΆistad M et al. | β | 2005 | β |
| Endogenous opiates and behavior: 2004. | Bodnar RJ et al. | β | 2005 | β |
| Morphine-6-glucuronide: actions and mechanisms. | Kilpatrick GJ et al. | β | 2005 | β |
| Polymorphism of mu-opioid receptor gene (OPRM1:c.118A>G) does not protect against opioid-induced respiratory depression despite reduced analgesic response. | Romberg RR et al. | β | 2005 | β |
| The contribution of genetics to addiction therapy approaches. | Edenberg HJ et al. | β | 2005 | β |
| The G protein-coupled receptors: pharmacogenetics and disease. | Thompson MD et al. | β | 2005 | β |